Arno Therapeutics, Inc.
ARNI · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.02 | -0.01 | -0.01 |
| FCF Yield | -141.54% | -138.48% | -67.68% | -51.87% |
| EV / EBITDA | -0.68 | -0.26 | 0.34 | -0.54 |
| Quality | ||||
| ROIC | 757.21% | -352.70% | -73.71% | -112.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | -2.42 | 0.36 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 47.06% | -32.18% | -51.20% | -37.38% |
| Safety | ||||
| Net Debt / EBITDA | -0.15 | 0.37 | 1.58 | 0.73 |
| Interest Coverage | -472.20 | -150,302.98 | -0.91 | -1.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -48,345.15 | 0.00 | 0.00 | 0.00 |